Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.53 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.53 |
| ▸ | PDE4A | P27815 | 6/20 | 0.52 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.52 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.52 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.52 |
| ▸ | TOP2A | P11388 | 1/20 | 0.49 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.45 |
| ▸ | SLC5A7 | Q9GZV3 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20697674 | 0.86 | KMT2A (0.57) | TAS1R3TAS1R1PDE4APDE4BPDE4C | |
| SCHEMBL19083822 | 0.86 | KMT2A (0.57) | TAS1R3TAS1R1PDE4APDE4BPDE4C | |
| SCHEMBL31389146 | 0.84 | TAS1R3 (0.63) | TAS1R3TAS1R1 | |
| SCHEMBL26148924 | 0.84 | TAS1R3 (0.63) | TAS1R3TAS1R1 | |
| SCHEMBL19083995 | 0.83 | TAS1R3 (0.62) | TAS1R3TAS1R1PDE4APDE4BPDE4C | |
| SCHEMBL19083996 | 0.79 | TAS1R3 (0.64) | TAS1R3TAS1R1PDE4APDE4BPDE4C | |
| SCHEMBL31389134 | 0.72 | TAS1R3 (0.68) | TAS1R3TAS1R1PDE4APDE4BPDE4C | |
| SCHEMBL26148923 | 0.72 | TAS1R3 (0.68) | TAS1R3TAS1R1PDE4APDE4BPDE4C | |
| SCHEMBL19083824 | 0.71 | POLB (0.49) | PDE4APDE4BPDE4CPDE4DUTS2R | |
| Hydrochloric Acid SCHEMBL3593654 | 0.70 | AKR1C3 (0.47) | PDE4APDE4BPDE4CPDE4DUTS2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C1R, MTX1 | TAS1R3 2742/4885TAS1R1 2598/4885PDE4A 449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.